Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Cash & Equivalents (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Cash & Equivalents for 15 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 15.15% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Sep 2025, up 15.15%, and an annual FY2024 reading of $1.1 million, down 82.0% over the prior year.
  • Cash & Equivalents was $1.9 million for Q3 2025 at Alaunos Therapeutics, down from $2.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $100.1 million in Q1 2021 and bottomed at $319000.0 in Q1 2025.
  • Average Cash & Equivalents over 5 years is $32.8 million, with a median of $18.3 million recorded in 2023.
  • Peak annual rise in Cash & Equivalents hit 16.89% in 2025, while the deepest fall reached 92.3% in 2025.
  • Year by year, Cash & Equivalents stood at $76.1 million in 2021, then plummeted by 48.64% to $39.1 million in 2022, then tumbled by 84.48% to $6.1 million in 2023, then crashed by 82.0% to $1.1 million in 2024, then soared by 77.64% to $1.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for TCRT at $1.9 million in Q3 2025, $2.9 million in Q2 2025, and $319000.0 in Q1 2025.